chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Eyes got blood shot red; Discomfort in her mouth; When she eats, chews or swallows, it stings, burns and is very painful/ mouth hurting as hell; Tip of her tongue also is purplish in color; Gums are swollen; Knees hyper extends; Tip of her tongue painful sensation; Inflammation she is having in her mouth; Itchiness felt for a day on the injection site; Felt tired for 3 weeks; Tenderness were also felt for a day on the injection site; This spontaneous case was reported by a consumer and describes the occurrence of OCULAR HYPERAEMIA (Eyes got blood shot red), ORAL DISCOMFORT (Discomfort in her mouth), ORAL PAIN (When she eats, chews or swallows, it stings, burns and is very painful/ mouth hurting as hell), TONGUE DISCOLOURATION (Tip of her tongue also is purplish in color) and GINGIVAL SWELLING (Gums are swollen) in a 51-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 047b21A and 017B21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On 27-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 24-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 24-Apr-2021, the patient experienced OCULAR HYPERAEMIA (Eyes got blood shot red), ORAL DISCOMFORT (Discomfort in her mouth), ORAL PAIN (When she eats, chews or swallows, it stings, burns and is very painful/ mouth hurting as hell), TONGUE DISCOLOURATION (Tip of her tongue also is purplish in color), GINGIVAL SWELLING (Gums are swollen), JOINT HYPEREXTENSION (Knees hyper extends), GLOSSODYNIA (Tip of her tongue painful sensation), STOMATITIS (Inflammation she is having in her mouth), VACCINATION SITE PRURITUS (Itchiness felt for a day on the injection site), FATIGUE (Felt tired for 3 weeks) and VACCINATION SITE PAIN (Tenderness were also felt for a day on the injection site). The patient was treated with PENICILLIN NOS for Pain inflammation activated, at an unspecified dose and frequency; IBUPROFEN (MOTRIN [IBUPROFEN]) for Pain inflammation activated, at an unspecified dose and frequency and Physical therapy for Joint hyperextension. At the time of the report, OCULAR HYPERAEMIA (Eyes got blood shot red), ORAL DISCOMFORT (Discomfort in her mouth), ORAL PAIN (When she eats, chews or swallows, it stings, burns and is very painful/ mouth hurting as hell), TONGUE DISCOLOURATION (Tip of her tongue also is purplish in color), GINGIVAL SWELLING (Gums are swollen), JOINT HYPEREXTENSION (Knees hyper extends), GLOSSODYNIA (Tip of her tongue painful sensation), STOMATITIS (Inflammation she is having in her mouth), VACCINATION SITE PRURITUS (Itchiness felt for a day on the injection site), FATIGUE (Felt tired for 3 weeks) and VACCINATION SITE PAIN (Tenderness were also felt for a day on the injection site) outcome was unknown.            No concomitant medications were reported.  Treatment medications included oral/numbing gel.  Action taken with mRNA-1273 in response to the events was  not applicable
Redness around injection site; Pain, swelling, itchiness at the inejction site; Experienced Itchiness 2 hours after getting it; Swelling at my right arm (injection site); A spontaneous report was received from a consumer concerning a 93-years-old, female patient who received Moderna's COVID-19 Vaccine, and who experienced itching around injection site, redness around the injection site and swelling around injection site.   The patient's medical history was not provided. Products known to have been used by the patient, within two weeks prior to the event, included Benadryl, Metoprolol, Atorvastatin, Lorazepan, Vitamin C, Euthyrox, Latanoprost, Dorzolamide/Timolol and Mupirocin.  On 16 Jan 2021, approximately two hours prior to the onset of the symptoms, the patient received their first of two planned doses of mRNA-1273 (Lot number 042L20A) intramuscularly in the right arm for prophylaxis of COVID-19 infection.    On 16 Jan 2021, the patient experienced itching around injection site, redness around the injection site and swelling around injection site Treatment for the event included ice pack and Benadryl.   Action taken with mRNA-1273 in response to the events was not provided.   The outcome of the events itching around injection site, redness around the injection site and swelling around injection site was not reported.
Vomiting for 1-2 days once on 1/12/17 @ 8:30pm and once on 1/13/17 @ 12:30am...1/12/17 @ 12:00pm rash on neck.
heart pain; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) for a Pfizer sponsored program. The reporter is the parent.  A female patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) at the age of 19 years as dose 1, single and (Batch/Lot number: unknown) as dose 2, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: ANGINA PECTORIS (medically significant), outcome "unknown", described as "heart pain". Clinical course: The reporter reported that the daughter (Patient) had received Covid vaccine and for some time had been complaining of heart pain that she associated at first not with the vaccine that is known to cause Myocarditis and Pericarditis but with energy drinks.  The lot number for bnt162b2 was not provided and will be requested during follow up.
pt recv vax & on 24MAR98 found to have a large knot @ the inj site w/petechiae & bruising from groin to hip;CBC results were nl;
Patient is claiming that she got cellulitis from the flu shot and that the vaccine was administered below the deltoid muscle and that she ended up in urgent care and got prescribed antibiotics for the cellulitis. She claims that she got the cellulitis 6 days post administration of the vaccines.
lying in bed sleeping; throat is dry.; swollen lymph nodes under her arms; muscle soreness; soreness (injection site); headache; coughing; tiredness; her chest hurts with exertion; fever; low appetite; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non-HCP) from medical information team. The reporter is the patient.  A 51-year-old female patient received bnt162b2 (BNT162B2), administered in arm left, administration date 22Sep2021 16:00 (Lot number: FF2588) at the age of 51 years as dose 1, single for covid-19 immunisation. Relevant medical history included: "covid-19", start date: 27Aug2021 (unspecified if ongoing), notes: she had symptoms of Covid on 27AUG2021, and tested positive on 01SEP2021; "overweight" (unspecified if ongoing). The patient's concomitant medications were not reported.  The following information was reported: HEADACHE (non-serious) with onset 22Sep2021, outcome "not recovered", described as "headache"; COUGH (non-serious) with onset 22Sep2021, outcome "not recovered", described as "coughing"; FATIGUE (non-serious) with onset 22Sep2021, outcome "not recovered", described as "tiredness"; CHEST PAIN (non-serious) with onset 22Sep2021, outcome "not recovered", described as "her chest hurts with exertion"; PYREXIA (non-serious) with onset 22Sep2021, outcome "unknown", described as "fever"; DECREASED APPETITE (non-serious) with onset 22Sep2021, outcome "unknown", described as "low appetite"; LYMPHADENOPATHY (non-serious) with onset 23Sep2021, outcome "unknown", described as "swollen lymph nodes under her arms"; VACCINATION SITE PAIN (non-serious) with onset 22Sep2021, outcome "recovering", described as "soreness (injection site)"; MYALGIA (non-serious) with onset 23Sep2021, outcome "not recovered", described as "muscle soreness"; SOMNOLENCE (non-serious), outcome "unknown", described as "lying in bed sleeping"; DRY THROAT (non-serious), outcome "unknown", described as "throat is dry.". Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were taken as a result of headache. Additional information: patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, was patient was diagnosed with covid, Since the vaccination, patient has been tested for covid   Follow-up (14Oct2021): Follow-up attempts are completed. No further information is expected.
Numbness in face beginning 20 minutes after vaccine, subsiding 5 hours later. This happened after both shots but was worse after the second dose. No other symptoms.; This is a spontaneous report from a contactable consumer, the patient. A 38-year-old female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: UNKNOWN) via an unspecified route of administration  on an unknown date and a second dose of BNT162b2(PFIZER BIONTECH COVID-19 mRNA VACCINE, Lot Number: UNKNOWN) via an unspecified route of administration in right arm on 02May2021(at the age of 38-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma. Concomitant medications included budesonide (PULMICORT), allium sativum (KYOLIC), vitamin d nos (VIT D) and budesonide (MANUFACTURER UNKNOWN), all from unknown dates and for unknown indications. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccination. On an unknown date in 2021, the patient experienced numbness in face. This happened after both shots but was worse after the second dose. The event began 20 minutes after second dose and subsided 5 hours later. The patient had no other symptoms. The adverse event resulted in doctor or other healthcare professional office/clinic visit. The clinical outcome of the event numbness in face was recovered on an unknown date in 2021.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Redness at the injection site.; Swelling at the injection site.; Pain at the injection site.; This case was reported by a consumer via call center representative and described the occurrence of injection site erythema in a 92-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 19th January 2023, the patient received Shingrix (intramuscular). On 20th January 2023, 1 days after receiving Shingrix, the patient experienced injection site erythema, injection site swelling and injection site pain. On an unknown date, the outcome of the injection site erythema, injection site swelling and injection site pain were not recovered/not resolved.   It was unknown if the reporter considered the injection site erythema, injection site swelling and injection site pain to be related to Shingrix.     Additional Information: GSK receipt date: 23 Jan 2023 Reporters comment: The reporter stated that the patient received the Shingrix vaccine on 19th January 2023 the following day she started feeling redness, swelling and pain at the injection site that is going away with ice pack.  Education provided on side effects. Patient refused to provide consent to follow up.
Patient was taken to the ER on Sunday July 15, 2019  & again on Monday July 16, 2019 in extreme pain, vomiting, and bloody stool.  He was ultimately diagnosed with Intussusception and life flighted to Hospital on Monday July 16, 2019.  Upon arrival, he received a barium enima which successfully reduced the Intussusception.  The next morning he re-intussuscepted and had another barium enima procedure.  Which again was sucessful.    Patient has since had a third episode of Intussusception in Nov. 2019.  This time it was corrected successfully with a air enima.
LOOSE STOOL/WATERY STOOL; This spontaneous case was reported by a consumer and describes the occurrence of DIARRHOEA (LOOSE STOOL/WATERY STOOL) in an elderly patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) solution for injection for Ulcerative colitis.    The patient's past medical history included Loose stools.   On 03-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 02-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 26-Oct-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) at an unspecified dose. On an unknown date, the patient experienced DIARRHOEA (LOOSE STOOL/WATERY STOOL). At the time of the report, DIARRHOEA (LOOSE STOOL/WATERY STOOL) was resolving.            No concomitant medication was reported.   Treatment information was not provided. This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.
The next day patient woke up with the area being red, raised but smooth, hot, and itching. 3 inches length and 2 inches wide. The patient was instructed to on 7/24/2017 when the pharmacy was informed to apply Vaseline and cover the area. She was also told to take BENADRYL 25mg. The patient contacted the pharmacy again on 7/27/17 because another area of the arm had developed 3 raised itchy areas. The patient was instructed to visit her medical doctor the next day for further evaluation.   On 8/1/2017 the pharmacy contacted the patient regarding her progress. The physician did not recommend any further treatment and advise patient to continue current recommendation. The patient reported that the skin irritations is almost heal and no longer bothersome.
Started as dull ache and has continued to increase to a more intense ache... taking Advil to be able to sleep.
Patient came in to the Hospital with blood in the urine since July 3.  Patient had been on Kleffx, and then called his own pcp.  Pcp adviced he get blood work done at the urgent care.  Urgent care was only able to do urine test.  Kleffix was discontined  and patient was then given Bactrium also Zofran.  Patient was complaining of eating very little , denied chest pain, denies SOB.  Complained of chills and shaking.  No other complaints,  Patient did have a chest x-ray.  Found on x-ray ground glassin the perfary of right lower lobe.  Diagnosis was , acute weakneess, phemonia, hematuria.
About 5 minutes after shot was administered patient became light headed and blacked out. right after patient  blacked out, he immediately came to. patient was also profusely sweating, and continued to be light headed. Patient was given water, and began feeling better. Patient stayed in the waiting area for about an hour until he no longer felt light headed, and stated that he felt much better. Patient also drank pedialyte and took some home with him to drink.
This spontaneous information as received from an Office Manager refers to a female patient of unknown age. Medical history and concomitant medication were not reported. On an unknown date the patient was vaccinated with ZOSTAVAX (dose, route, lot number and expiration date were not reported). On an unknown date the patient experienced mild reaction to ZOSTAVAX. The outcome of event is unknown. It was not reported if the patient sought medical attention. This is one of several reports from the same source. Additional information has been requested.
fatigue; rib cage pain; joint pain; no appetite; dry eyes; mild sinusitis; This is a spontaneous report from a contactable consumer. A female patient of an unspecified age received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Solution for injection, Batch/Lot number was not reported), dose 1 via an unspecified route of administration on 23Feb2021 as dose 1, single for COVID-19 immunisation. The patient medical history and concomitant medications were not reported. On an unspecified date in Feb2021, consumer experienced fatigue, rib cage pain, joint pain, no appetite, dry eyes and mild sinusitis. Patient was scheduled on 16Mar2021 for her second dose. Patient asked if she can still take the second dose and what was the percentage that the vaccine will be effective. The outcome of events was unknown.  No follow-up attempts are possible; information about lot/batch number cannot be obtained
I felt a tightness in my chest, wheezing, a fever, sore throat, coughing, sinus congestion, phlegm going down my throat, general malaise. I used my home COVID-19 test and it came back positive. I emailed my doctor, she had one of the nurses call me, we discussed my symptoms, she prescribed the PAXLOVID, I started taking it immediately. I have not gotten rebound COVID-19 and am feeling much better.
pt recv vax 12APR96 & in office on 17JUN98 chickenpox dx;
No symptoms or additional adverse effects reported; Patient received unspecified dose in VAQTA immunization series that was improperly stored; This spontaneous report was received from a medical assistant referring to a 2 years old patient of unknown gender. Information about pertinent medical history, drug reactions/allergies and concomitant medication was not reported.  On 11-JUN-2020, the patient was vaccinated with an unspecified dose of hepatitis a vaccine, inactivated (VAQTA) (lot # S030587 with expiration date 06-JAN-2021, dose detail and route were not reported) for prophylaxis.        The vaccine experienced improperly stored and was stored at 50 Fahrenheit degrees (F) for 34 minutes. There was no previous temperature excursion. The call was because of a data logger involved. No symptoms or additional adverse effects were reported.
Severe headache, chills, fever, night sweats, painful heartbeat, insomnia, cough, muscle aches, confusion
ADMINISTRATION ERROR, PATIENT WANTS JOHNSON AND JOHNSON BUT WE GAVE PFIZER
I am having moderate joint pains and sporadic heart palpitations and racing heart. Ongoing.
fever, h/a, body aches, cough, sore throat, arm soreness, breathing diff w/chest pain;sxs started @ 2PM took Advil for fever, cough syrup for cough p/2hrs coughing; next day slept all day sick; arm still sore-weak
On July 22, I noticed a rash on my arm, my face and small spots on my body. On July 24, the rash on my arm went away, but my face continued to itch, so I saw my dermatologist and urgent care. I was given a topical cream for the face and an antihistamine for the itching.  On August 1, I started to feel nausea, dizziness and loss of appetite. On August  3 I took a COVID test and it was negative, so this is likely related to the vaccine. On August 3 I noticed more blisters forming (a total of 3-4 new ones, one of which was on my lip)
This spontaneous report as received from a nurse practitioner refers to an unspecified number of school-aged children of unknown gender. The patients' pertinent medical history and drug reactions or allergies were not reported. On unknown dates (reported as "in the past"), the patients were vaccinated with unknown doses of VARIVAX (route and site of administration, lot # and expiry date were not reported). Concomitant medications were not reported). On unknown dates, the patients developed breakthrough varicella even though the patients had previously received VARIVAX. It was unspecified how many doses of VARIVAX the patients had received prior to developing breakthrough varicella. The outcome of the event was unknown. The relatedness between the event and VARIVAX was not reported. Additional information has been requested.
9 days p/vax pt developed fever accompanied by rt focal sz; she had nl MRI study, EEG is pending.
Four days after the shot I started coughing and spitting up cold.  Friday I continue coughing, spitting, and had a fever.  Saturday coughing  continue and a running nose.  Sunday coughing and running nose continues. Monday running nose and head cold symptoms.  Tuesday is the first day I felt better even though I felt completly dry.
Crotch pain; Red Lump on arm; Hot lump on arm; Pain in arm; Collarbone pain; Lump on collarbone; Pain in armpit; Red lump on arm; Lump in armpit; Low grade fever; This spontaneous case was reported by a consumer and describes the occurrence of AXILLARY MASS (Lump in armpit), GROIN PAIN (Crotch pain), VACCINATION SITE MASS (Red Lump on arm), VACCINATION SITE WARMTH (Hot lump on arm) and PAIN IN EXTREMITY (Pain in arm) in a 38-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 042L20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 19-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 25-Feb-2021, the patient experienced PYREXIA (Low grade fever). On 27-Feb-2021, the patient experienced AXILLARY MASS (Lump in armpit). On 28-Feb-2021, the patient experienced GROIN PAIN (Crotch pain), VACCINATION SITE MASS (Red Lump on arm), VACCINATION SITE WARMTH (Hot lump on arm), PAIN IN EXTREMITY (Pain in arm), BONE PAIN (Collarbone pain), MASS (Lump on collarbone), AXILLARY PAIN (Pain in armpit) and VACCINATION SITE ERYTHEMA (Red lump on arm). At the time of the report, AXILLARY MASS (Lump in armpit), GROIN PAIN (Crotch pain), VACCINATION SITE MASS (Red Lump on arm), VACCINATION SITE WARMTH (Hot lump on arm), PAIN IN EXTREMITY (Pain in arm), BONE PAIN (Collarbone pain), MASS (Lump on collarbone), AXILLARY PAIN (Pain in armpit), VACCINATION SITE ERYTHEMA (Red lump on arm) and PYREXIA (Low grade fever) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was not provided by the reporter.  Treatment of the events included aspirin   This case was linked to MOD-2021-099036 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 29-Apr-2021: Follow-up was received and outcome of the events, email address of reporter were updated
pt recv vax on 14JAN97;15JAN97 pt exp a h/a, chills & tingling of the skin on hand;the event required visit to ER or MD visit
No adverse reaction. Wrong concentration of Moderna Bivalent vaccine given. The patient was to receive the Moderna Bivalent Booster (blue cap) that had 0.25mcg/0.25ml but received 0.2 from the pink cap Pediatric vial that had 10mcg/0.2ml. Lower dose then needed given.
JOINTS AND MUSCLE ACHES GENERAL MALAISE EAR PLUGGED BLADDER URGENCY, BURNING TYLENOL STEROID SHOT
ADMINISTRATION OF HALF A DOSE FOR BOOSTER SHOT; This spontaneous report received from a physician concerned a patient of unspecified age and sex of unspecified race and ethnic origin.  The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported.  On an Unspecified date the patient was previously treated with covid-19 vaccine ad26. cov2.s from unspecified manufacturer (Dose Number in Series: 1) for prophylactic vaccination and did not report any adverse events.  The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown expiry: unknown) 50 %, start therapy date was not reported, 1 total administered for prophylactic vaccination. The batch number was not reported and has been requested. (Dose Number in Series: 2) No concomitant medications were reported.  On an unspecified date, the patient experienced administration of half a dose for booster shot. (Dose Number in Series: 2)  The action taken with covid-19 vaccine ad26.cov2.s was not applicable.  The outcome of administration of half a dose for booster shot was not reported.  This report was non-serious.
"Clear blisters, now cloudy with erythematous bases." Diagnosis: Varicella Treatment: None